TELA Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TELA Bio, Inc. on April 23, 2020, reporting events that occurred on April 20, 2020. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Malvern, Pennsylvania. Its common stock trades on the Nasdaq Global Market under the symbol "TELA."
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
The filing reports significant changes to the composition of the Board of Directors effective April 20, 2020:
- Resignations: Ronald Ellis, Ashley Friedman, and Matthew Zuga resigned from the Board and their respective committees. The Company stated these resignations were not due to any disagreement with the Company regarding operations, policies, or practices.
- Appointments: Lisa Colleran and Doug Evans were appointed as Class I directors. Both are considered independent under Nasdaq listing rules.
- Committee Assignments:
- Lisa Colleran: Audit Committee and Nominating and Corporate Governance Committee.
- Doug Evans: Chairperson of the Board, Audit Committee, and Compensation Committee.
Compensation and Governance Details
In connection with their appointments, the Board granted stock options and established annual retainers for the new directors:
- Initial Stock Options: Each director received options to purchase 8,000 shares of Common Stock under the 2019 Equity Incentive Plan. These vest in 36 equal monthly installments starting May 20, 2020.
- Annual Base Retainers:
- Lisa Colleran: $40,000 (Board) + $10,000 (Audit Committee) + $5,000 (Nominating Committee) = $55,000 total.
- Doug Evans: $40,000 (Board) + $35,000 (Board Chair) + $10,000 (Audit Committee) + $7,500 (Compensation Committee) = $92,500 total.
- Annual Equity Award: Each director will receive an annual option award with an aggregate fair value of $80,000 on the grant date, vesting on the earlier of the first anniversary of the grant or the subsequent annual meeting.
Investor Verification Checklist
- Verify the independence status of Lisa Colleran and Doug Evans under Nasdaq listing rules.
- Confirm the total number of outstanding shares and the impact of the new option grants on dilution.
- Review the Company's 2019 Equity Incentive Plan to understand the remaining share pool available for future grants.
- Monitor the upcoming 2020 annual meeting of stockholders where the new Class I directors will stand for re-election.